KYMERA THERAPEUTICS ($KYMR) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.97 per share, missing estimates of -$0.82 by $0.15. The company also reported revenue of $2,870,000, missing estimates of $15,093,960 by $-12,223,960.
You can see Quiver Quantitative's $KYMR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KYMERA THERAPEUTICS Insider Trading Activity
KYMERA THERAPEUTICS insiders have traded $KYMR stock on the open market 52 times in the past 6 months. Of those trades, 2 have been purchases and 50 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- BROS. ADVISORS LP BAKER has made 2 purchases buying 2,005,813 shares for an estimated $172,499,918 and 0 sales.
- BRUCE BOOTH has made 0 purchases and 14 sales selling 236,588 shares for an estimated $21,699,043.
- NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 12 sales selling 220,000 shares for an estimated $17,266,488.
- JARED GOLLOB (Chief Medical Officer) has made 0 purchases and 11 sales selling 111,997 shares for an estimated $8,217,926.
- BRUCE N. JACOBS (Chief Financial Officer) sold 79,220 shares for an estimated $3,961,380
- PAMELA ESPOSITO has made 0 purchases and 9 sales selling 35,563 shares for an estimated $2,856,271.
- JEFFREY W. ALBERS has made 0 purchases and 3 sales selling 10,000 shares for an estimated $744,772.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KYMERA THERAPEUTICS Hedge Fund Activity
We have seen 157 institutional investors add shares of KYMERA THERAPEUTICS stock to their portfolio, and 120 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,048,963 shares (+51.9%) to their portfolio in Q4 2025, for an estimated $237,239,811
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,542,550 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $197,835,815
- BAKER BROS. ADVISORS LP added 2,005,813 shares (+30.2%) to their portfolio in Q4 2025, for an estimated $156,072,309
- AVORO CAPITAL ADVISORS LLC added 1,124,747 shares (+17.7%) to their portfolio in Q4 2025, for an estimated $87,516,564
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,061,957 shares (+20.8%) to their portfolio in Q4 2025, for an estimated $82,630,874
- ALLIANCEBERNSTEIN L.P. added 903,296 shares (+1852.2%) to their portfolio in Q4 2025, for an estimated $70,285,461
- VANGUARD GROUP INC added 845,922 shares (+15.6%) to their portfolio in Q4 2025, for an estimated $65,821,190
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KYMERA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $KYMR in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/03/2026
- Stephens & Co. issued a "Overweight" rating on 12/11/2025
- Mizuho issued a "Outperform" rating on 12/11/2025
- JP Morgan issued a "Overweight" rating on 12/10/2025
- Leerink Partners issued a "Outperform" rating on 12/09/2025
- Jefferies issued a "Buy" rating on 12/09/2025
- B of A Securities issued a "Buy" rating on 12/09/2025
To track analyst ratings and price targets for KYMERA THERAPEUTICS, check out Quiver Quantitative's $KYMR forecast page.
KYMERA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $KYMR recently. We have seen 18 analysts offer price targets for $KYMR in the last 6 months, with a median target of $119.0.
Here are some recent targets:
- Jeet Mukherjee from BTIG set a target price of $138.0 on 02/03/2026
- Etzer Darout from Barclays set a target price of $133.0 on 01/28/2026
- Kalpit Patel from B. Riley Securities set a target price of $117.0 on 12/22/2025
- Brian Abrahams from RBC Capital set a target price of $103.0 on 12/16/2025
- Sudan Loganathan from Stephens & Co. set a target price of $110.0 on 12/11/2025
- Joseph Catanzaro from Mizuho set a target price of $120.0 on 12/11/2025
- Brian Cheng from JP Morgan set a target price of $125.0 on 12/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
